Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/CSNK1G1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/CSNK1G1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/CSNK1G1_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/CSNK1G1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/CSNK1G1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001605532 | Oral cavity | NEOLP | Wnt signaling pathway | 93/2005 | 444/18723 | 1.35e-10 | 1.34e-08 | 93 |
GO:019873832 | Oral cavity | NEOLP | cell-cell signaling by wnt | 93/2005 | 446/18723 | 1.73e-10 | 1.66e-08 | 93 |
GO:001810522 | Oral cavity | NEOLP | peptidyl-serine phosphorylation | 70/2005 | 315/18723 | 1.97e-09 | 1.24e-07 | 70 |
GO:001820922 | Oral cavity | NEOLP | peptidyl-serine modification | 72/2005 | 338/18723 | 7.84e-09 | 4.09e-07 | 72 |
GO:003011131 | Oral cavity | NEOLP | regulation of Wnt signaling pathway | 70/2005 | 328/18723 | 1.17e-08 | 5.67e-07 | 70 |
GO:006082831 | Oral cavity | NEOLP | regulation of canonical Wnt signaling pathway | 55/2005 | 253/18723 | 2.23e-07 | 7.28e-06 | 55 |
GO:006007031 | Oral cavity | NEOLP | canonical Wnt signaling pathway | 62/2005 | 303/18723 | 3.79e-07 | 1.15e-05 | 62 |
GO:009026331 | Oral cavity | NEOLP | positive regulation of canonical Wnt signaling pathway | 29/2005 | 106/18723 | 1.40e-06 | 3.56e-05 | 29 |
GO:003017723 | Oral cavity | NEOLP | positive regulation of Wnt signaling pathway | 33/2005 | 140/18723 | 9.57e-06 | 1.82e-04 | 33 |
GO:00160559 | Prostate | BPH | Wnt signaling pathway | 126/3107 | 444/18723 | 2.27e-10 | 1.23e-08 | 126 |
GO:01987389 | Prostate | BPH | cell-cell signaling by wnt | 126/3107 | 446/18723 | 3.11e-10 | 1.67e-08 | 126 |
GO:00301119 | Prostate | BPH | regulation of Wnt signaling pathway | 95/3107 | 328/18723 | 1.23e-08 | 3.99e-07 | 95 |
GO:00608289 | Prostate | BPH | regulation of canonical Wnt signaling pathway | 75/3107 | 253/18723 | 1.47e-07 | 3.43e-06 | 75 |
GO:00600709 | Prostate | BPH | canonical Wnt signaling pathway | 84/3107 | 303/18723 | 6.54e-07 | 1.27e-05 | 84 |
GO:00301778 | Prostate | BPH | positive regulation of Wnt signaling pathway | 43/3107 | 140/18723 | 2.45e-05 | 2.93e-04 | 43 |
GO:00181059 | Prostate | BPH | peptidyl-serine phosphorylation | 79/3107 | 315/18723 | 7.09e-05 | 6.96e-04 | 79 |
GO:00902638 | Prostate | BPH | positive regulation of canonical Wnt signaling pathway | 33/3107 | 106/18723 | 1.55e-04 | 1.36e-03 | 33 |
GO:00182097 | Prostate | BPH | peptidyl-serine modification | 82/3107 | 338/18723 | 1.73e-04 | 1.48e-03 | 82 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CSNK1G1 | SNV | Missense_Mutation | novel | c.904N>T | p.Pro302Ser | p.P302S | Q9HCP0 | protein_coding | deleterious(0.03) | possibly_damaging(0.839) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
CSNK1G1 | SNV | Missense_Mutation | rs779009615 | c.488N>A | p.Arg163Gln | p.R163Q | Q9HCP0 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-MA-AA41-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
CSNK1G1 | SNV | Missense_Mutation | novel | c.898N>C | p.Glu300Gln | p.E300Q | Q9HCP0 | protein_coding | deleterious(0.02) | benign(0.41) | TCGA-VS-A958-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
CSNK1G1 | SNV | Missense_Mutation | | c.1100G>A | p.Arg367Gln | p.R367Q | Q9HCP0 | protein_coding | tolerated(0.11) | benign(0.246) | TCGA-G4-6306-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
CSNK1G1 | SNV | Missense_Mutation | novel | c.581N>G | p.Tyr194Cys | p.Y194C | Q9HCP0 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CSNK1G1 | SNV | Missense_Mutation | | c.508T>G | p.Phe170Val | p.F170V | Q9HCP0 | protein_coding | deleterious(0.02) | probably_damaging(0.997) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CSNK1G1 | SNV | Missense_Mutation | | c.38G>A | p.Arg13Gln | p.R13Q | Q9HCP0 | protein_coding | deleterious_low_confidence(0.03) | benign(0.145) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
CSNK1G1 | SNV | Missense_Mutation | rs145663344 | c.766N>A | p.Ala256Thr | p.A256T | Q9HCP0 | protein_coding | deleterious(0.01) | probably_damaging(0.973) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CSNK1G1 | SNV | Missense_Mutation | rs377487424 | c.452G>A | p.Arg151Gln | p.R151Q | Q9HCP0 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-AP-A1E0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | SD |
CSNK1G1 | SNV | Missense_Mutation | | c.692N>A | p.Arg231Lys | p.R231K | Q9HCP0 | protein_coding | deleterious(0) | probably_damaging(0.979) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
53944 | CSNK1G1 | SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, ENZYME | inhibitor | 249565843 | | |
53944 | CSNK1G1 | SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, ENZYME | | PF-562271 | PF-00562271 | |
53944 | CSNK1G1 | SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, ENZYME | | CENISERTIB | CENISERTIB | |
53944 | CSNK1G1 | SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, ENZYME | | ALSTERPAULLONE | ALSTERPAULLONE | |
53944 | CSNK1G1 | SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, ENZYME | | ILORASERTIB | ILORASERTIB | |
53944 | CSNK1G1 | SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, ENZYME | | CHIR-99021 | CHIR-99021 | |
53944 | CSNK1G1 | SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, ENZYME | inhibitor | 363894217 | VORUCICLIB | |
53944 | CSNK1G1 | SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, ENZYME | | CYC-116 | CYC-116 | |
53944 | CSNK1G1 | SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, ENZYME | | PHA-767491 | CHEMBL225519 | |
53944 | CSNK1G1 | SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, ENZYME | | (RS)-ROSCOVITINE | (RS)-ROSCOVITINE | |